Takeda Pharmaceutical (TAK) Total Non-Current Liabilities: 2017-2025

Historic Total Non-Current Liabilities for Takeda Pharmaceutical (TAK) over the last 9 years, with Mar 2025 value amounting to $31.5 billion.

  • Takeda Pharmaceutical's Total Non-Current Liabilities fell 15.46% to $31.5 billion in Q1 2025 from the same period last year, while for Mar 2025 it was $31.5 billion, marking a year-over-year decrease of 15.46%. This contributed to the annual value of $31.5 billion for FY2025, which is 17.60% down from last year.
  • Per Takeda Pharmaceutical's latest filing, its Total Non-Current Liabilities stood at $31.5 billion for FY2025, which was down 17.60% from $38.3 billion recorded in FY2024.
  • In the past 5 years, Takeda Pharmaceutical's Total Non-Current Liabilities ranged from a high of $56.2 billion in FY2021 and a low of $31.5 billion during FY2025.
  • Its 3-year average for Total Non-Current Liabilities is $35.9 billion, with a median of $37.9 billion in 2023.
  • In the last 5 years, Takeda Pharmaceutical's Total Non-Current Liabilities grew by 3.29% in 2021 and then decreased by 20.43% in 2023.
  • Over the past 5 years, Takeda Pharmaceutical's Total Non-Current Liabilities (MRY) stood at $56.2 billion in 2021, then decreased by 15.29% to $47.6 billion in 2022, then dropped by 20.43% to $37.9 billion in 2023, then grew by 1.00% to $38.3 billion in 2024, then fell by 17.60% to $31.5 billion in 2025.
  • Its last three reported values are $31.5 billion in FY2025, $38.3 billion for FY2024, and $37.9 billion during FY2023.